
The BioHub - by Avetix
Max Brennan - Biotech HeadHunterAudio
- Format:
- Podcast
- New episodes:
- Several times a week
- Typical length:
- about 30 minutes
- Latest episode:
About this show
Welcome to The BioHub, where the doors to the world of biotechnology swing wide open. Join your host, Max Brennan, a seasoned biotech recruiter, as he engages in thought-provoking conversations with the brightest minds in biotech. This podcast is your backstage pass to the insights, strategies, and stories that fuel success in the dynamic and ever-evolving biotech landscape.
Subscribe now and be part of the conversation that's shaping the future of biotechnology.
Get ready for an immersive experience into the world of biotech with The BioHub.
Covers: biotechnology, drug discovery, biotech careers, AI in drug development, clinical trials, biotech leadership, computational biology, rare diseases
Show details and episodes come from the publisher's public feed at anchor.fm. Last updated . Names, artwork and text belong to their publishers.
Recently on this show
Summary of recent episodes, drawn from the publisher's feed.
The BioHub is a podcast hosted by biotech recruiter Max Brennan, who talks with leading people in biotechnology about the strategies and stories behind their work. Recent episodes cover machine learning in drug discovery, treatments for cannabis use disorder, and overcoming drug resistance in cancer.
Cosmos
Similar in subject
- The Genetics Podcast
Both cover: drug discovery, rare diseases - BiotechTV - News
Both cover: biotechnology, clinical trials - The BioCentury Show
Both cover: rare diseases, clinical trials
Similar shows
- The Biotech Startups Podcast
- The Bitter Truth About Food Podcast
- The BoldlyGo Podcast: Revolutionizing Your Journey
- The Brainy Business | Understanding the Psychology of Why People Buy | Behavioral Economics
- The Brülosophy Podcast
- The Building Science Podcast
- The Bulletproof Musician
- The chemical breakdown & Chemistry in its element
Explore more
Episodes
Episode 219 - Prakash Raman - CEO of InduPro Therapeutics
· 36 min
We were delighted to be joined by Prakash Raman, Ph.D., CEO of InduPro Therapeutics. Prakash brings more than two decades of experience across the biopharmaceutical industry, spanning business development, licensing, portfolio strategy, venture creation and executive leadership. Before joining InduPro, he was President and CEO of Ribon Therapeutics, following a period as Senior Partner and Chief Business Development Officer at Flagship Pioneering. Prior to that, he spent almost 14 years at Novartis, ultimately becoming Global Head of Business Development and Licensing for NIBR, where he was involved in a number of significant partnerships and acquisitions. Today at InduPro, Prakash is helping build a company around a differentiated proximity biology platform, using an understanding of how proteins interact and are spatially organised to develop new therapeutics across oncology and immunology. The company has recently announced a $77 million Series B, entered into collaborations with companies including Lilly, Sanofi and Lonza, and has moved its lead programme, IDP-001, into the clinic. So today, we’re going to talk about Prakash’s journey through biotech, what he learned from operating inside big pharma and venture, how he thinks about building companies and platforms, the opportunity around proximity biology, and what it takes to translate a differentiated scientific idea into a successful biotech business.
Not rated yetEpisode 218 - JD Finley & Mitch Jones - Palisade Bio
· 23 min
On this episode we're joined by Palisade Bio's CEO & CMO, JD Finley & Mitch Jones. In Q2 2026, Palisade released promising ph1 data for their lead asset - PALI2108 - a PDE4 inhibitor. With recent IND clearance for their ph2 ASCENTRA-UC study, we discuss that data, and what real success looks like clinically & commercially for the business & asset moving forward, in an increasingly busy IBD market. We hope you enjoy the episode.
Not rated yetEpisode 217 - Kristen Wong - Partner Altitude VC
· 27 min
In this episode of The BioHub by Avetix, I’m joined by Kristen Wong of Altitude Life Science Ventures. Kristen shares her journey into venture capital and how she thinks about identifying the people and companies worth backing at the earliest stages. We discuss why the investments you pass on can be just as valuable as the ones you make, the importance of founder emotional intelligence, and what the SVB crisis taught her about supporting companies through uncertainty. We also explore where AI is genuinely changing biotech and investing, why Kristen writes about the industry, and the lessons she has learned from working closely with founders and company builders.
Not rated yetEpisode 216 - Tom Ciulla - CEO Ikarovec
· 20 min
In this episode we meet Tom Ciulla, CEO of Ikarovec, one of the most exciting gene therapy biotechs in The UK and the ophthalmology scene more broadly. Ikarovec isn't Tom's first rodeo - playing a role in the rise of Iveric, Spark, Viridian, and Nanoscope - but as a first-time CEO, tune in to hear what excited him the most about Ikarovec's bicistronic platform, their plans for clinical trials in GA & RP, and the latest on their Series A.
Not rated yetEpisode 215 - Nykode - Michael & Agnete - CEO & CSO
· 37 min
In this episode of The BioHub by Avetix, I’m joined by Michael Engsig, CEO of Nykode Therapeutics, and Agnete Fredriksen, Co-Founder and Chief Scientific Officer. Michael and Agnete share the story behind Nykode, how the company’s technology has evolved, and what they’ve learned from building a biotech around a novel approach to immunotherapy. We also discuss the balance between scientific ambition and commercial execution, the challenges of developing new cancer treatments, how the CEO and CSO roles work together, and where they see the future of cancer immunotherapy heading.
Not rated yetEpisode 214 - David Crean - CBO at MediciNova
· 33 min
In this episode of The BioHub Podcast by Avetix, Ben sits down with Dr. David Crean, Chief Business Officer at MediciNova, to explore a career spanning biotechnology, investment, M&A and strategic partnering. The conversation explores David’s journey into biotech, how he evaluates opportunities and partnerships, and the decisions that shape the development of emerging therapeutics. We also discuss MediciNova’s work in neurological disease, including the development of MN-166 (ibudilast), and the challenges of advancing therapies in areas such as ALS and other complex CNS disorders. David also shares his perspective on business development in today’s biotech market, what makes an asset attractive to potential partners, how smaller companies can position themselves effectively, and how the relationship between science, financing and deal-making has evolved throughout his career.
Not rated yetEpisode 215 - Kathleen Gallagher - CEO at Atrium Therapeutics
· 37 min
We were delighted to be joined by Kathleen Gallagher, CEO of Atrium Therapeutics. Kathleen has built a fascinating career across the biotech industry, with experience spanning corporate communications, investor relations, clinical development and executive leadership. Before founding Atrium, she spent time at companies including Merrimack Pharmaceuticals and Akcea Therapeutics, before joining Avidity Biosciences, where she ultimately became Chief Program Officer. At Avidity, Kathleen was closely involved in the company’s evolution and the development of its RNA therapeutics platform, including its work in myotonic dystrophy. The company’s journey ultimately culminated in its landmark acquisition by Novartis for up to $12 billion, one of the largest transactions in the biotech sector. Following that experience, Kathleen took on the CEO of Atrium Therapeutics. Atrium is developing targeted RNA therapies for genetically driven cardiovascular diseases, with the ambition of addressing serious rare diseases where patients currently have limited treatment options. Today, we’re going to talk about Kathleen’s journey through biotech, how her career evolved from communications and investor relations into drug development and ultimately the CEO role, what she learned from helping build Avidity, and what it was like to go through such a significant company transaction. We’ll also explore the opportunity in RNA therapeutics, the decision to start Atrium, what it takes to build a biotech from the ground up, and Kathleen’s perspective on leadership, culture and what makes an early-stage biotech successful.
Not rated yetEpisode 213 - Fred Aslan - CEO Artiva Bio
· 29 min
In this episode of The BioHub by Avetix, I’m joined by Fred Aslan, President and CEO of Artiva Biotherapeutics. Fred shares his journey across venture capital, business development and biotech leadership, including his time at Venrock and Vividion, and how those experiences shaped the way he now leads Artiva. We discuss what it takes to build and scale a biotech, how investor experience changes the way you make decisions as a CEO, the opportunity for off-the-shelf cell therapies, and where Fred sees the future of the cell therapy space heading.
Not rated yetEpisode 212 - Luis Pena - Founder & CEO Evommune
· 20 min
In this episode of The BioHub by Avetix, I’m joined by Luis Peña, Co-Founder, President and CEO of Evommune. Luis shares his journey from scientist to biotech founder, including the story behind building Dermira and the lessons he took from its acquisition by Eli Lilly. We discuss why he decided to start again with Evommune and the company’s ambition to develop new treatments for chronic inflammatory diseases. We also explore what it takes to build and finance a biotech, the transition into the CEO role, how Luis approaches leadership, and what he believes separates companies that successfully turn strong science into meaningful medicines.
Not rated yetEpisode 211 - Meredith Kaya - Corsera Health
· 16 min
In Q1 of this year, I sat down with Meredith, CFO at Corsera Health, to discuss the future of cardiovascular health and why prediction and prevention are becoming increasingly important in improving outcomes long before a CVD diagnosis.We explored what it takes to build a company at the intersection of science, data and healthcare, how finance and strategy support innovation.A really insightful conversation with Meredith on the opportunities and challenges of building a company focused on tackling one of the world's leading causes of death.
Not rated yet